Dan Leonard, MA, president, National Pharmaceutical Council, says the AMCP-ISPOR-NPC comparative effectiveness research collaboration is an effort that supports data management. Health plan stakeholders can visit cercollaborative.org to find a variety of information while analyzing and comparing the latest research findings. He suggests that other tools on the site also offer an educational benefit.

Although healthcare stakeholders view comparative effectiveness research (CER) as important to healthcare, respondents to a survey from the National Pharmaceutical Council admitted that they haven’t yet seen the impact of CER.

The pharmaceutical industry mounted a new challenge to a federal plan that would require generic drug companies to take the initiative to update their labels to warn consumers whenever health risks were discovered.